IVERIC bio Inc (NASDAQ: ISEE) recently received a written agreement from the USFDA under a Special Protocol Assessment (SPA) for the GATHER2 trial. This trial involves the company’s lead candidate Zimura®, which is meant to treat Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The SPA is a procedure […]